APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gastric Inhibitory Polypeptide Receptor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gastric Inhibitory Polypeptide Receptor Market Analysis and Forecast 2026-2032

Report ID 173994100222 December 2025190 pages

Choose your research edition.

Industry ResearchGastric Inhibitory Polypeptide Receptor Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Inhibitory Polypeptide Receptor Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Gastric Inhibitory Polypeptide Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Inhibitory Polypeptide Receptor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Inhibitory Polypeptide Receptor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gastric Inhibitory Polypeptide Receptor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Gastric Inhibitory Polypeptide Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gastric Inhibitory Polypeptide Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gastric Inhibitory Polypeptide Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gastric Inhibitory Polypeptide Receptor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Gastric Inhibitory Polypeptide Receptor include Sanofi, Novo Nordisk A/S, AstraZeneca Plc, Zealand Pharma A/S, Longevity Biotech, Inc, Diabetica Limited, Carmot Therapeutics, Inc. and Alchemia Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Gastric Inhibitory Polypeptide Receptor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gastric Inhibitory Polypeptide Receptor, also provides the sales of main regions and countries. Of the upcoming market potential for Gastric Inhibitory Polypeptide Receptor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastric Inhibitory Polypeptide Receptor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gastric Inhibitory Polypeptide Receptor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Gastric Inhibitory Polypeptide Receptor sales, projected growth trends, production technology, application and end-user industry.

Gastric Inhibitory Polypeptide Receptor Segment by Company

Sanofi

Novo Nordisk A/S

AstraZeneca Plc

Zealand Pharma A/S

Longevity Biotech, Inc

Diabetica Limited

Carmot Therapeutics, Inc.

Alchemia Limited

Gastric Inhibitory Polypeptide Receptor Segment by Type

HM-15211

LBT-6030

LY-3298176

NNC-92041706

Others

Gastric Inhibitory Polypeptide Receptor Segment by Application

Obesity

Metabolic Disorder

Type 2 Diabetes

Others

Gastric Inhibitory Polypeptide Receptor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Inhibitory Polypeptide Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Inhibitory Polypeptide Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Inhibitory Polypeptide Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Gastric Inhibitory Polypeptide Receptor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Gastric Inhibitory Polypeptide Receptor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastric Inhibitory Polypeptide Receptor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. HM-15211 Major Manufacturers Table 3. LBT-6030 Major Manufacturers Table 4. LY-3298176 Major Manufacturers Table 5. NNC-92041706 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Obesity Major Manufacturers Table 9. Metabolic Disorder Major Manufacturers Table 10. Type 2 Diabetes Major Manufacturers Table 11. Others Major Manufacturers Table 12. Gastric Inhibitory Polypeptide Receptor Industry Trends Table 13. Gastric Inhibitory Polypeptide Receptor Industry Drivers Table 14. Gastric Inhibitory Polypeptide Receptor Industry Opportunities and Challenges Table 15. Gastric Inhibitory Polypeptide Receptor Industry Restraints Table 16. Global Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2021-2026) Table 20. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2027-2032) Table 21. Global Gastric Inhibitory Polypeptide Receptor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 22. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2026) & (k units) Table 23. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2027-2032) & (k units) Table 24. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2021-2026) Table 25. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2027-2032) Table 26. Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Manufacturers (2021-2026) Table 30. Global Gastric Inhibitory Polypeptide Receptor Sales Price (US$/unit) of Manufacturers (2021-2026) Table 31. Global Gastric Inhibitory Polypeptide Receptor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Gastric Inhibitory Polypeptide Receptor Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Gastric Inhibitory Polypeptide Receptor Manufacturers, Product Type & Application Table 34. Global Gastric Inhibitory Polypeptide Receptor Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Gastric Inhibitory Polypeptide Receptor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2021-2026) Table 41. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2027-2032) Table 42. Global Gastric Inhibitory Polypeptide Receptor Sales by Type 2021 VS 2025 VS 2032 (k units) Table 43. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 44. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 45. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2021-2026) Table 46. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2027-2032) Table 47. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2026) & (US$/unit) Table 48. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2027-2032) & (US$/unit) Table 49. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2021-2026) Table 53. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2027-2032) Table 54. Global Gastric Inhibitory Polypeptide Receptor Sales by Application 2021 VS 2025 VS 2032 (k units) Table 55. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 56. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 57. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2021-2026) Table 58. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2027-2032) Table 59. Global Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2026) & (US$/unit) Table 60. Global Gastric Inhibitory Polypeptide Receptor Price by Application (2027-2032) & (US$/unit) Table 61. Sanofi Company Information Table 62. Sanofi Business Overview Table 63. Sanofi Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 64. Sanofi Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 65. Sanofi Recent Development Table 66. Novo Nordisk A/S Company Information Table 67. Novo Nordisk A/S Business Overview Table 68. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 70. Novo Nordisk A/S Recent Development Table 71. AstraZeneca Plc Company Information Table 72. AstraZeneca Plc Business Overview Table 73. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 75. AstraZeneca Plc Recent Development Table 76. Zealand Pharma A/S Company Information Table 77. Zealand Pharma A/S Business Overview Table 78. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 80. Zealand Pharma A/S Recent Development Table 81. Longevity Biotech, Inc Company Information Table 82. Longevity Biotech, Inc Business Overview Table 83. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 85. Longevity Biotech, Inc Recent Development Table 86. Diabetica Limited Company Information Table 87. Diabetica Limited Business Overview Table 88. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 90. Diabetica Limited Recent Development Table 91. Carmot Therapeutics, Inc. Company Information Table 92. Carmot Therapeutics, Inc. Business Overview Table 93. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 95. Carmot Therapeutics, Inc. Recent Development Table 96. Alchemia Limited Company Information Table 97. Alchemia Limited Business Overview Table 98. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio Table 100. Alchemia Limited Recent Development Table 101. North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 104. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 105. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2021-2026) & (US$/unit) Table 106. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2027-2032) & (US$/unit) Table 107. North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 110. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 111. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2021-2026) & (US$/unit) Table 112. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2027-2032) & (US$/unit) Table 113. North America Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 115. North America Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 116. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 117. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (k units) Table 118. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032) & (k units) Table 119. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2021-2026) & (US$/unit) Table 120. North America Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2027-2032) & (US$/unit) Table 121. United States Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 122. Canada Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 123. Mexico Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 124. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 127. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 128. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2021-2026) & (US$/unit) Table 129. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2027-2032) & (US$/unit) Table 130. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 133. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 134. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2021-2026) & (US$/unit) Table 135. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2027-2032) & (US$/unit) Table 136. Europe Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. Europe Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 140. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (k units) Table 141. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032) & (k units) Table 142. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2021-2026) & (US$/unit) Table 143. Europe Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2027-2032) & (US$/unit) Table 144. Germany Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 145. France Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 146. U.K. Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 147. Italy Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 148. Russia Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 149. Spain Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 150. Netherlands Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 151. Switzerland Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 152. Sweden Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 153. Poland Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 154. China Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 155. China Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 156. China Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 157. China Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 158. China Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2021-2026) & (US$/unit) Table 159. China Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2027-2032) & (US$/unit) Table 160. China Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 161. China Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 162. China Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 163. China Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 164. China Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2021-2026) & (US$/unit) Table 165. China Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2027-2032) & (US$/unit) Table 166. Asia Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 167. Asia Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 168. Asia Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 169. Asia Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 170. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2021-2026) & (US$/unit) Table 171. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2027-2032) & (US$/unit) Table 172. Asia Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 173. Asia Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 174. Asia Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 175. Asia Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 176. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2021-2026) & (US$/unit) Table 177. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2027-2032) & (US$/unit) Table 178. Asia Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. Asia Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 180. Asia Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 181. Asia Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 182. Asia Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (k units) Table 183. Asia Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032) & (k units) Table 184. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2021-2026) & (US$/unit) Table 185. Asia Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2027-2032) & (US$/unit) Table 186. Japan Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 187. South Korea Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 188. India Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 189. Australia Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 190. Taiwan Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 191. Southeast Asia Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 192. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (US$ Million) Table 193. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Type (2027-2032) & (US$ Million) Table 194. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (k units) Table 195. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Type (2027-2032) & (k units) Table 196. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2021-2026) & (US$/unit) Table 197. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Type (2027-2032) & (US$/unit) Table 198. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (US$ Million) Table 199. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Application (2027-2032) & (US$ Million) Table 200. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (k units) Table 201. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Application (2027-2032) & (k units) Table 202. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2021-2026) & (US$/unit) Table 203. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Application (2027-2032) & (US$/unit) Table 204. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 208. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (k units) Table 209. SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Country (2027-2032) & (k units) Table 210. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2021-2026) & (US$/unit) Table 211. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Price by Country (2027-2032) & (US$/unit) Table 212. Brazil Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 213. Argentina Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 214. Chile Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 215. Colombia Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 216. Peru Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 217. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 218. Israel Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 219. UAE Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 220. Turkey Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 221. Iran Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 222. Egypt Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Gastric Inhibitory Polypeptide Receptor Distributors List Table 226. Gastric Inhibitory Polypeptide Receptor Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Gastric Inhibitory Polypeptide Receptor Image Figure 2. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Inhibitory Polypeptide Receptor Market Size Share 2021 VS 2025 VS 2032 Figure 4. HM-15211 Image Figure 5. LBT-6030 Image Figure 6. LY-3298176 Image Figure 7. NNC-92041706 Image Figure 8. Others Image Figure 9. Global Gastric Inhibitory Polypeptide Receptor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Gastric Inhibitory Polypeptide Receptor Market Size Share 2021 VS 2025 VS 2032 Figure 11. Obesity Image Figure 12. Metabolic Disorder Image Figure 13. Type 2 Diabetes Image Figure 14. Others Image Figure 15. Global Gastric Inhibitory Polypeptide Receptor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Gastric Inhibitory Polypeptide Receptor Revenue (2021-2032) & (US$ Million) Figure 17. Global Gastric Inhibitory Polypeptide Receptor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2021-2032) Figure 20. Global Gastric Inhibitory Polypeptide Receptor Sales (2021-2032) & (k units) Figure 21. Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 22. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Gastric Inhibitory Polypeptide Receptor Sales YoY (2021-2032) & (k units) Figure 24. Europe Gastric Inhibitory Polypeptide Receptor Sales YoY (2021-2032) & (k units) Figure 25. China Gastric Inhibitory Polypeptide Receptor Sales YoY (2021-2032) & (k units) Figure 26. Asia (Excluding China) Gastric Inhibitory Polypeptide Receptor Sales YoY (2021-2032) & (k units) Figure 27. South America, Middle East and Africa Gastric Inhibitory Polypeptide Receptor Sales YoY (2021-2032) & (k units) Figure 28. Global Gastric Inhibitory Polypeptide Receptor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Gastric Inhibitory Polypeptide Receptor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2021-2032) Figure 34. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 35. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2021-2032) Figure 37. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2021-2032) Figure 40. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 41. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2021-2032) Figure 43. North America Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2021-2032) Figure 44. North America Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2021-2032) Figure 45. North America Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2021-2032) Figure 46. North America Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2021-2032) Figure 47. North America Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2021-2032) Figure 48. North America Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2021-2032) Figure 49. Europe Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2021-2032) Figure 50. Europe Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2021-2032) Figure 51. Europe Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2021-2032) Figure 52. Europe Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2021-2032) Figure 53. Europe Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2021-2032) Figure 54. Europe Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2021-2032) Figure 55. China Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2021-2032) Figure 56. China Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2021-2032) Figure 57. China Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2021-2032) Figure 58. China Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2021-2032) Figure 59. Asia Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2021-2032) Figure 60. Asia Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2021-2032) Figure 61. Asia Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2021-2032) Figure 62. Asia Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2021-2032) Figure 63. Asia Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2021-2032) Figure 64. Asia Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2021-2032) Figure 65. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Share by Type (2021-2032) Figure 66. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Share by Type (2021-2032) Figure 67. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Share by Application (2021-2032) Figure 68. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Share by Application (2021-2032) Figure 69. SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Share by Country (2021-2032) Figure 70. SAMEA Gastric Inhibitory Polypeptide Receptor Sales Share by Country (2021-2032) Figure 71. Gastric Inhibitory Polypeptide Receptor Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Gastric Inhibitory Polypeptide Receptor Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • HM-15211
  • LBT-6030
  • LY-3298176
  • NNC-92041706
  • Others
Applications
  • Obesity
  • Metabolic Disorder
  • Type 2 Diabetes
  • Others
Companies covered
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca Plc
  • Zealand Pharma A/S
  • Longevity Biotech, Inc
  • Diabetica Limited
  • Carmot Therapeutics, Inc.
  • Alchemia Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gastric Inhibitory Polypeptide Receptor Market by Type
  3. 1.2.1 Global Gastric Inhibitory Polypeptide Receptor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 HM-15211
  5. 1.2.3 LBT-6030
  6. 1.2.4 LY-3298176
  7. 1.2.5 NNC-92041706
  8. 1.2.6 Others
  9. 1.3 Gastric Inhibitory Polypeptide Receptor Market by Application
  10. 1.3.1 Global Gastric Inhibitory Polypeptide Receptor Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Obesity
  12. 1.3.3 Metabolic Disorder
  13. 1.3.4 Type 2 Diabetes
  14. 1.3.5 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Gastric Inhibitory Polypeptide Receptor Market Dynamics
  1. 2.1 Gastric Inhibitory Polypeptide Receptor Industry Trends
  2. 2.2 Gastric Inhibitory Polypeptide Receptor Industry Drivers
  3. 2.3 Gastric Inhibitory Polypeptide Receptor Industry Opportunities and Challenges
  4. 2.4 Gastric Inhibitory Polypeptide Receptor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Gastric Inhibitory Polypeptide Receptor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region
  3. 3.2.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2021-2026)
  5. 3.2.3 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2027-2032)
  6. 3.2.4 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Gastric Inhibitory Polypeptide Receptor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Gastric Inhibitory Polypeptide Receptor Sales by Region
  9. 3.4.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2026)
  11. 3.4.3 Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2027-2032)
  12. 3.4.4 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers
  2. 4.1.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Gastric Inhibitory Polypeptide Receptor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturers
  6. 4.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Gastric Inhibitory Polypeptide Receptor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Gastric Inhibitory Polypeptide Receptor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Gastric Inhibitory Polypeptide Receptor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Gastric Inhibitory Polypeptide Receptor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Gastric Inhibitory Polypeptide Receptor Manufacturers, Product Type & Application
  13. 4.7 Global Gastric Inhibitory Polypeptide Receptor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Gastric Inhibitory Polypeptide Receptor Market CR5 and HHI
  16. 4.8.2 2025 Gastric Inhibitory Polypeptide Receptor Tier 1, Tier 2, and Tier 3
5 Gastric Inhibitory Polypeptide Receptor Market by Type
  1. 5.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type
  2. 5.1.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Type
  6. 5.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2021-2032)
  9. 5.3 Global Gastric Inhibitory Polypeptide Receptor Price by Type
6 Gastric Inhibitory Polypeptide Receptor Market by Application
  1. 6.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application
  2. 6.1.1 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Application
  6. 6.2.1 Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2021-2032)
  9. 6.3 Global Gastric Inhibitory Polypeptide Receptor Price by Application
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Gastric Inhibitory Polypeptide Receptor Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Novo Nordisk A/S
  8. 7.2.1 Novo Nordisk A/S Company Information
  9. 7.2.2 Novo Nordisk A/S Business Overview
  10. 7.2.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
  12. 7.2.5 Novo Nordisk A/S Recent Developments
  13. 7.3 AstraZeneca Plc
  14. 7.3.1 AstraZeneca Plc Company Information
  15. 7.3.2 AstraZeneca Plc Business Overview
  16. 7.3.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product Portfolio
  18. 7.3.5 AstraZeneca Plc Recent Developments
  19. 7.4 Zealand Pharma A/S
  20. 7.4.1 Zealand Pharma A/S Company Information
  21. 7.4.2 Zealand Pharma A/S Business Overview
  22. 7.4.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product Portfolio
  24. 7.4.5 Zealand Pharma A/S Recent Developments
  25. 7.5 Longevity Biotech, Inc
  26. 7.5.1 Longevity Biotech, Inc Company Information
  27. 7.5.2 Longevity Biotech, Inc Business Overview
  28. 7.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product Portfolio
  30. 7.5.5 Longevity Biotech, Inc Recent Developments
  31. 7.6 Diabetica Limited
  32. 7.6.1 Diabetica Limited Company Information
  33. 7.6.2 Diabetica Limited Business Overview
  34. 7.6.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
  36. 7.6.5 Diabetica Limited Recent Developments
  37. 7.7 Carmot Therapeutics, Inc.
  38. 7.7.1 Carmot Therapeutics, Inc. Company Information
  39. 7.7.2 Carmot Therapeutics, Inc. Business Overview
  40. 7.7.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product Portfolio
  42. 7.7.5 Carmot Therapeutics, Inc. Recent Developments
  43. 7.8 Alchemia Limited
  44. 7.8.1 Alchemia Limited Company Information
  45. 7.8.2 Alchemia Limited Business Overview
  46. 7.8.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product Portfolio
  48. 7.8.5 Alchemia Limited Recent Developments
8 North America
  1. 8.1 North America Gastric Inhibitory Polypeptide Receptor Market Size by Type
  2. 8.1.1 North America Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
  3. 8.1.2 North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
  4. 8.1.3 North America Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
  5. 8.2 North America Gastric Inhibitory Polypeptide Receptor Market Size by Application
  6. 8.2.1 North America Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
  7. 8.2.2 North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
  8. 8.2.3 North America Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
  9. 8.3 North America Gastric Inhibitory Polypeptide Receptor Market Size by Country
  10. 8.3.1 North America Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Gastric Inhibitory Polypeptide Receptor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Type
  2. 9.1.1 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
  3. 9.1.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
  4. 9.1.3 Europe Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
  5. 9.2 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Application
  6. 9.2.1 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
  7. 9.2.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
  8. 9.2.3 Europe Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
  9. 9.3 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Country
  10. 9.3.1 Europe Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Gastric Inhibitory Polypeptide Receptor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Gastric Inhibitory Polypeptide Receptor Market Size by Type
  2. 10.1.1 China Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
  3. 10.1.2 China Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
  4. 10.1.3 China Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
  5. 10.2 China Gastric Inhibitory Polypeptide Receptor Market Size by Application
  6. 10.2.1 China Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
  7. 10.2.2 China Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
  8. 10.2.3 China Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gastric Inhibitory Polypeptide Receptor Market Size by Type
  2. 11.1.1 Asia Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
  3. 11.1.2 Asia Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
  4. 11.1.3 Asia Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
  5. 11.2 Asia Gastric Inhibitory Polypeptide Receptor Market Size by Application
  6. 11.2.1 Asia Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
  7. 11.2.2 Asia Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
  8. 11.2.3 Asia Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
  9. 11.3 Asia Gastric Inhibitory Polypeptide Receptor Market Size by Country
  10. 11.3.1 Asia Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Gastric Inhibitory Polypeptide Receptor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gastric Inhibitory Polypeptide Receptor Market Size by Type
  2. 12.1.1 SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2032)
  5. 12.2 SAMEA Gastric Inhibitory Polypeptide Receptor Market Size by Application
  6. 12.2.1 SAMEA Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2032)
  9. 12.3 SAMEA Gastric Inhibitory Polypeptide Receptor Market Size by Country
  10. 12.3.1 SAMEA Gastric Inhibitory Polypeptide Receptor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Gastric Inhibitory Polypeptide Receptor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Gastric Inhibitory Polypeptide Receptor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Gastric Inhibitory Polypeptide Receptor Value Chain Analysis
  2. 13.1.1 Gastric Inhibitory Polypeptide Receptor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Gastric Inhibitory Polypeptide Receptor Production Mode & Process
  6. 13.2 Gastric Inhibitory Polypeptide Receptor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Gastric Inhibitory Polypeptide Receptor Distributors
  9. 13.2.3 Gastric Inhibitory Polypeptide Receptor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst